Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106672 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
A Phase 1 study of Myasthenia Gravis and AChR Myasthenia Gravis, sponsored by COUR Pharmaceutical Development Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 17
- Study locations
NCT06106672 is a Phase 1 study of Myasthenia Gravis and AChR Myasthenia Gravis that is actively recruiting participants, run by COUR Pharmaceutical Development Company. The registered enrollment target is 54 participants, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (72% lower). The trial reports 17 study locations across 12 states.
The verdict
NCT06106672, a Phase 1 study of Myasthenia Gravis and AChR Myasthenia Gravis, is actively recruiting participants, sponsored by COUR Pharmaceutical Development Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 17
- Study locations
Study Summary
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CNP-106
Study Locations (17)
Florida
- Atlantis Research - Miami
- Quantix Research, LLC - Miami
- University of South Florida - Tampa
Arizona
- Barrow Neurological Institute - Phoenix
- Neuromuscular Clinic and Research Center - Phoenix
California
- Infusion for Health - Brea
- University of California, Irvine - Orange
Texas
- Nerve and Muscle Center of Texas - Houston
- Prolato Clinical Research Center - Houston
Connecticut
- Yale University - New Haven
Illinois
- Insight Hospital and Medical Center - Chicago
Kansas
- University of Kansas Medical Center - Kansas City
Michigan
- Insight Research Institute, Dearborn - Dearborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106672
The ClinicalTrials.gov registry entry for NCT06106672 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (72% lower). The listed sponsor is COUR Pharmaceutical Development Company, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06106672 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06106672 about?
NCT06106672 is a clinical study titled "Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis". Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
What is the current status of trial NCT06106672?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2024-05-30. Estimated completion is 2026-08.
What conditions does trial NCT06106672 study?
This clinical trial studies the following conditions: Myasthenia Gravis, AChR Myasthenia Gravis, Generalized Myasthenia, MuSK MG.
What interventions are being tested in trial NCT06106672?
The interventions under investigation include: Placebo (OTHER), CNP-106 (DRUG).
Who is sponsoring clinical trial NCT06106672?
This trial is sponsored by COUR Pharmaceutical Development Company, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106672 being conducted?
This trial has 17 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
RECRUITING · Phase 1
-
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
RECRUITING · Phase 1
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.